Bristol Myelodysplastic Syndromes Therapy OKd

 

• Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia based on interim results from pivotal Phase 3 COMMANDS trial, expanding approved population to ESA-naïve patients, regardless of ring sideroblast status
• In head-to-head study, results showed Reblozyl nearly doubled the percent of patients achieving primary endpoint of concurrent transfusion independence and hemoglobin (Hb) increase vs. epoetin alfa, with a well-established safety profile

https://www.biospace.com/article/releases/u-s-fda-approves-bristol-myers-squibb-s-reblozyl-luspatercept-aamt-as-first-line-treatment-of-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes-mds-who-may-require-transfusions/